While patients who undergo percutaneous closure of ventricular septal defect (VSD) have a high rate of in-hospital mortality, long-term outcomes are generally favorable in those who survive to ...
Percutaneous closure of symptomatic ventricular septal defects in children can be achieved with off-label use of an occluder device. A research letter published online November 7, 2012, ahead of print ...
Percutaneous closure can be described as a less-invasive surgical procedure used to treat patients with atrial septal defect (ASD) or patent foramen ovale (PFO). Since the utilization of percutaneous ...
April 10, 2009 (Boston, Massachusetts and Vancouver, British Columbia) — The FDA has granted premarket approval to the Starflex device (NMT Medical) for the treatment of ventricular septal defects ...
Isolated ventricular septal defect (VSD) is the most common congenital heart disease. [9] Some of them evolve in spontaneous closure or do not cause hemodynamically significant shunt and do not need ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced its development program for PerQseal ® ...
Chennai's TNGMSSH has performed over 31,000 cardiac procedures in 10 years, highlighting its excellence in cardiac care.
Nonrandomized studies have shown that patients who undergo percutaneous coronary intervention (PCI) can be safely discharged from hospital after a short observation period, but these trials were ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical today announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable percutaneous vascular closure device for large-bore ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback